
Top Healthcare Dividend Stocks: Our 5 Picks for November 2026
Healthcare dividend stocks span insurers, distributors, diagnostics, medical devices, and branded medicines in this five-stock November 2026 countdown.
Every article, report, and earnings note where JNJ appears.

Healthcare dividend stocks span insurers, distributors, diagnostics, medical devices, and branded medicines in this five-stock November 2026 countdown.

Johnson & Johnson is a Buy as newer medicines and MedTech growth offset STELARA’s decline. The stock looks fairly valued to slightly attractive with strong cash generation and a broad pipeline.

Johnson & Johnson (JNJ) drops after a mixed Q3 earnings report. The company beat adjusted EPS and revenue estimates and raised guidance, but reported profit fell and MedTech sales faced Middle East-related pressure, prompting investors to reassess the stock’s premium valuation.

A five-stock big pharma countdown spans vaccines, oncology, immunology and MedTech, featuring Amgen, Pfizer and Johnson & Johnson among diversified names.

A three-stock countdown explores medical devices through women’s-health diagnostics, orthopedic implants and robotic surgery, with valuation, profitability and earnings data for each company.

Eli Lilly's next move looks less like a pipeline trade and more like an access trade. Demand was never the problem; broader PBM coverage and expected Medicare access starting July 1 make the revenue conversion story more immediate.

Healthcare’s leadership over tech and semis looks less like a defensive flinch and more like a valuation message from a still-hawkish market. With rates staying restrictive, investors are rewarding nearer-term earnings durability and demanding a higher bar for crowded long-duration growth.

Our seven-stock Dividend Kings countdown spans industrials, healthcare, beverages, restaurants and household staples, with four lower-ranked names available in the free portion.

A seven-stock countdown spans beverages, restaurants, biopharmaceuticals and consumer staples, showing how dividend growth can blend income, defensiveness and earnings durability.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate JNJ ReportCancel anytime